Выбор темы
Выбор стиля шрифта
Novartis новости
01/02
Отчет иностранного эмитента (6-K) - NOVARTIS AG
03/02
🔗
Seeking Alpha: Novartis: A Good Long-Term Pick
02/02
🔗
Seeking Alpha: Novartis AG (NVS) CEO Vasant Narasimhan on Q4 2021 Results - Earnings Call Transcript
02/02
🔗
Zacks Investment Research: Novartis (NVS) Q4 Earnings & Sales Miss, Sandoz Review Ongoing
02/02
🔗
Benzinga: Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues
02/02
🔗
CNBC International TV: Committed to growing over 4% through 2026, says Novartis CEO
02/02
🔗
Reuters: Novartis Q4 core operating income gains 9%
02/02
🔗
GuruFocus: Sale Rumors of Novartis' Sandoz Unit Are Heating Up
01/02
🔗
Benzinga: Carlyle, Blackstone Mull $25B Buyout For Novartis' Sandoz Arm: Report
12/01
🔗
CNBC Television: Novartis CEO: We're moving toward filing Covid drug from Molecular Partners with FDA
11/01
🔗
Zacks Investment Research: Molecular (MOLN), Novartis Post Positive Data From COVID-19 Drug
10/01
🔗
Barrons: Molecular Partners Stock Surges as Novartis Plans to License Covid-19 Drug
10/01
🔗
Benzinga: Novartis To In-License COVID-19 Treatment From Molecular Partners, After Encouraging Mid-Stage Data
08/01
🔗
Zacks Investment Research: Novartis (NVS) Partners With Alnylam for Liver-Targeted Therapies
04/01
🔗
Reuters: Novartis says U.S. court upholds Gilenya patent
29/12
🔗
Invezz: Top biotech stocks to watch in 2022
23/12
🔗
Zacks Investment Research: Novartis (NVS) Gets FDA Nod for Cosentyx's Label Expansion
23/12
🔗
The Motley Fool: Novartis Eyes Up to $1.5 Billion for Gene Therapy Firm
22/12
🔗
Zacks Investment Research: Novartis (NVS) to Buy Gyroscope, Submits Herceptin Biosimilar to EMA
20/12
🔗
Benzinga: Novartis Inks Option Agreement For BeiGene Anti-Cancer Therapy For Over $1 Billion
20/12
🔗
Benzinga: Novartis' Ligelizumab Suffers Setback In Late-Stage Skin Disorder Studies
16/12
🔗
Pulse2: Novartis Stock (NVS): Why The Price Increased Today
16/12
🔗
Reuters: Novartis launches new share buyback of up to $15 billion
14/12
🔗
Benzinga: Molecular Partners Inks License Deal With Novartis For $580M
11/12
🔗
Reuters: Novartis sees strong interest in Sandoz generics unit - Finanz und Wirtschaft
10/12
🔗
Reuters: Novartis CEO says Sandoz attracting interest - paper
09/12
🔗
24/7 Wall Street: Biotech Has Been Crushed: 5 Stocks to Buy Now That Pay Big Dividends
02/12
🔗
InvestorPlace: AUPH Stock: The Novartis Takeover Talk That Has Aurinia Pharma Shares Taking Off Today
02/12
🔗
Reuters: Novartis sees annual sales growth of 4% until 2026
30/11
🔗
Reuters: Novartis chairman says all options open for Sandoz unit - report
29/11
🔗
Seeking Alpha: Novartis: Management Should Repurchase The Discounted Stock
27/11
🔗
GuruFocus: A Trio of International Health Care Stocks for Income
Загрузить еще